| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myeloproliferative Disorders | 5 | 2023 | 110 | 3.550 |
Why?
|
| Leukemia, Myeloid, Acute | 13 | 2024 | 763 | 2.690 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2024 | 375 | 1.970 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 9 | 2024 | 878 | 1.890 |
Why?
|
| Aminopyridines | 2 | 2023 | 38 | 1.660 |
Why?
|
| Janus Kinase Inhibitors | 2 | 2023 | 19 | 1.640 |
Why?
|
| Triazines | 2 | 2023 | 53 | 1.640 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2023 | 346 | 1.330 |
Why?
|
| Antineoplastic Agents | 4 | 2023 | 2360 | 1.010 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2023 | 51 | 0.940 |
Why?
|
| Aniline Compounds | 1 | 2023 | 55 | 0.940 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 53 | 0.920 |
Why?
|
| Pyrazines | 1 | 2023 | 92 | 0.910 |
Why?
|
| Lymphoma, B-Cell | 1 | 2022 | 103 | 0.820 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2021 | 16 | 0.790 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2021 | 21 | 0.790 |
Why?
|
| Bridged-Ring Compounds | 1 | 2020 | 13 | 0.780 |
Why?
|
| Thrombocytopenia | 2 | 2021 | 183 | 0.760 |
Why?
|
| Pyrrolidines | 1 | 2020 | 58 | 0.750 |
Why?
|
| Benzamides | 1 | 2020 | 229 | 0.720 |
Why?
|
| Lymphoma, Follicular | 1 | 2020 | 70 | 0.710 |
Why?
|
| Sulfonamides | 2 | 2024 | 300 | 0.710 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2021 | 98 | 0.710 |
Why?
|
| Neoplasms, Second Primary | 1 | 2021 | 252 | 0.680 |
Why?
|
| Disease Management | 4 | 2020 | 327 | 0.640 |
Why?
|
| Pyrimidines | 1 | 2020 | 370 | 0.630 |
Why?
|
| Humans | 41 | 2024 | 86643 | 0.570 |
Why?
|
| Disease Susceptibility | 3 | 2020 | 193 | 0.530 |
Why?
|
| Blast Crisis | 2 | 2023 | 33 | 0.450 |
Why?
|
| Antibodies, Bispecific | 3 | 2021 | 21 | 0.440 |
Why?
|
| Retreatment | 2 | 2022 | 107 | 0.400 |
Why?
|
| Enzyme Inhibitors | 2 | 2023 | 639 | 0.370 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2023 | 589 | 0.350 |
Why?
|
| Mutation | 6 | 2023 | 3968 | 0.350 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 2262 | 0.330 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 257 | 0.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 2438 | 0.310 |
Why?
|
| Remission Induction | 3 | 2024 | 722 | 0.290 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2023 | 127 | 0.280 |
Why?
|
| Disease Progression | 2 | 2020 | 1531 | 0.280 |
Why?
|
| Treatment Outcome | 5 | 2021 | 7993 | 0.270 |
Why?
|
| Prospective Studies | 2 | 2023 | 4213 | 0.240 |
Why?
|
| Oleic Acids | 1 | 2023 | 26 | 0.240 |
Why?
|
| Hepatitis B | 1 | 2024 | 74 | 0.230 |
Why?
|
| Janus Kinase 2 | 1 | 2023 | 57 | 0.220 |
Why?
|
| Philadelphia Chromosome | 1 | 2022 | 38 | 0.220 |
Why?
|
| Middle Aged | 8 | 2023 | 25028 | 0.220 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 1565 | 0.210 |
Why?
|
| Cytogenetics | 1 | 2021 | 27 | 0.210 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2023 | 592 | 0.210 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 262 | 0.210 |
Why?
|
| Leukemia | 1 | 2024 | 320 | 0.210 |
Why?
|
| Immunocompetence | 1 | 2021 | 27 | 0.200 |
Why?
|
| Castleman Disease | 1 | 2021 | 13 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2021 | 109 | 0.200 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 567 | 0.200 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 2271 | 0.200 |
Why?
|
| Uridine | 1 | 2021 | 56 | 0.200 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 45 | 0.200 |
Why?
|
| Male | 8 | 2021 | 40965 | 0.200 |
Why?
|
| Janus Kinases | 1 | 2020 | 23 | 0.190 |
Why?
|
| Clonal Evolution | 1 | 2020 | 15 | 0.190 |
Why?
|
| Papillomavirus Vaccines | 1 | 2021 | 58 | 0.190 |
Why?
|
| Translocation, Genetic | 1 | 2021 | 265 | 0.190 |
Why?
|
| Patient Outcome Assessment | 1 | 2021 | 84 | 0.190 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 365 | 0.190 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2024 | 381 | 0.190 |
Why?
|
| Azacitidine | 1 | 2021 | 137 | 0.190 |
Why?
|
| Chromosome Aberrations | 1 | 2021 | 387 | 0.180 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 111 | 0.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 559 | 0.180 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 44 | 0.180 |
Why?
|
| Feedback | 1 | 2020 | 133 | 0.180 |
Why?
|
| Education, Medical, Graduate | 2 | 2020 | 369 | 0.180 |
Why?
|
| Uncertainty | 1 | 2019 | 71 | 0.170 |
Why?
|
| Drug Resistance | 1 | 2020 | 256 | 0.170 |
Why?
|
| Patient Care | 1 | 2020 | 100 | 0.170 |
Why?
|
| Young Adult | 5 | 2024 | 5976 | 0.170 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2018 | 13 | 0.170 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 357 | 0.170 |
Why?
|
| Exercise | 1 | 2022 | 315 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 266 | 0.160 |
Why?
|
| Proteasome Inhibitors | 1 | 2018 | 51 | 0.160 |
Why?
|
| Environment | 1 | 2020 | 219 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 185 | 0.160 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 239 | 0.160 |
Why?
|
| Retrospective Studies | 8 | 2024 | 8489 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 371 | 0.160 |
Why?
|
| Genomics | 2 | 2020 | 720 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2020 | 427 | 0.150 |
Why?
|
| Neoplasms | 2 | 2023 | 2898 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1313 | 0.150 |
Why?
|
| Patient Care Team | 1 | 2019 | 280 | 0.150 |
Why?
|
| Recurrence | 1 | 2020 | 1139 | 0.150 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 379 | 0.150 |
Why?
|
| Referral and Consultation | 1 | 2019 | 328 | 0.150 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 418 | 0.140 |
Why?
|
| Aged | 7 | 2023 | 18415 | 0.140 |
Why?
|
| Prognosis | 2 | 2024 | 3679 | 0.140 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1686 | 0.140 |
Why?
|
| Adolescent | 4 | 2024 | 8981 | 0.140 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 469 | 0.140 |
Why?
|
| Internal Medicine | 1 | 2019 | 347 | 0.140 |
Why?
|
| HIV Infections | 1 | 2024 | 772 | 0.130 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 1464 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 6509 | 0.130 |
Why?
|
| Age Factors | 1 | 2020 | 1851 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1169 | 0.130 |
Why?
|
| Blood Pressure | 1 | 2021 | 1143 | 0.130 |
Why?
|
| Adult | 7 | 2024 | 25648 | 0.130 |
Why?
|
| Risk Factors | 2 | 2023 | 5417 | 0.130 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 1939 | 0.130 |
Why?
|
| Biomarkers | 1 | 2020 | 1718 | 0.120 |
Why?
|
| Internship and Residency | 2 | 2020 | 1004 | 0.120 |
Why?
|
| Signal Transduction | 2 | 2023 | 3241 | 0.120 |
Why?
|
| Sweet Syndrome | 1 | 2013 | 5 | 0.120 |
Why?
|
| Sin3 Histone Deacetylase and Corepressor Complex | 1 | 2012 | 3 | 0.110 |
Why?
|
| Histone Deacetylase 2 | 1 | 2012 | 6 | 0.110 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2012 | 148 | 0.100 |
Why?
|
| Histones | 1 | 2012 | 311 | 0.090 |
Why?
|
| Female | 4 | 2020 | 44532 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 329 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 536 | 0.080 |
Why?
|
| Animals | 3 | 2023 | 26582 | 0.070 |
Why?
|
| Fever | 2 | 2021 | 125 | 0.070 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 724 | 0.070 |
Why?
|
| Clinical Competence | 2 | 2022 | 751 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 2426 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2012 | 1565 | 0.060 |
Why?
|
| Dairy Products | 1 | 2023 | 11 | 0.060 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2023 | 4 | 0.060 |
Why?
|
| Red Meat | 1 | 2023 | 10 | 0.060 |
Why?
|
| Consolidation Chemotherapy | 1 | 2024 | 22 | 0.060 |
Why?
|
| Bilirubin | 1 | 2024 | 125 | 0.060 |
Why?
|
| Fatty Acids, Volatile | 1 | 2023 | 32 | 0.060 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2023 | 66 | 0.060 |
Why?
|
| Milk | 1 | 2023 | 53 | 0.060 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 76 | 0.060 |
Why?
|
| bcl-X Protein | 1 | 2023 | 52 | 0.060 |
Why?
|
| Sheep | 1 | 2023 | 239 | 0.060 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2023 | 35 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2023 | 107 | 0.060 |
Why?
|
| Cytarabine | 1 | 2024 | 218 | 0.060 |
Why?
|
| Cattle | 1 | 2023 | 376 | 0.060 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 78 | 0.060 |
Why?
|
| Cyclic AMP | 1 | 2023 | 273 | 0.060 |
Why?
|
| Neoplasm, Residual | 1 | 2024 | 162 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 189 | 0.050 |
Why?
|
| Acute Disease | 1 | 2024 | 826 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2023 | 233 | 0.050 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 17 | 0.050 |
Why?
|
| Nuclear Proteins | 2 | 2018 | 696 | 0.050 |
Why?
|
| Transplantation Conditioning | 1 | 2023 | 373 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 86 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2023 | 996 | 0.050 |
Why?
|
| Fatigue | 1 | 2021 | 174 | 0.050 |
Why?
|
| Allografts | 1 | 2021 | 172 | 0.050 |
Why?
|
| Withholding Treatment | 1 | 2020 | 112 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2022 | 170 | 0.050 |
Why?
|
| Minority Groups | 1 | 2021 | 137 | 0.050 |
Why?
|
| United States | 2 | 2024 | 6672 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 226 | 0.040 |
Why?
|
| Weight Loss | 1 | 2021 | 229 | 0.040 |
Why?
|
| Vaccination | 1 | 2021 | 254 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2020 | 103 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 916 | 0.040 |
Why?
|
| Burnout, Professional | 1 | 2020 | 94 | 0.040 |
Why?
|
| Boron Compounds | 1 | 2018 | 20 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2018 | 72 | 0.040 |
Why?
|
| Glycine | 1 | 2018 | 92 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2018 | 285 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 236 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 295 | 0.040 |
Why?
|
| Mice | 2 | 2023 | 11352 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 1538 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 458 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 508 | 0.040 |
Why?
|
| Apoptosis | 1 | 2023 | 1683 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2018 | 579 | 0.030 |
Why?
|
| Chicago | 1 | 2019 | 1379 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2767 | 0.030 |
Why?
|
| Phenotype | 1 | 2020 | 2378 | 0.030 |
Why?
|
| Leukocytosis | 1 | 2013 | 16 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1197 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2012 | 3 | 0.030 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2012 | 10 | 0.030 |
Why?
|
| Co-Repressor Proteins | 1 | 2012 | 18 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2013 | 105 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 86 | 0.030 |
Why?
|
| Protein Subunits | 1 | 2012 | 122 | 0.030 |
Why?
|
| Physicians | 1 | 2019 | 673 | 0.030 |
Why?
|
| Histone Deacetylases | 1 | 2012 | 63 | 0.030 |
Why?
|
| Neutrophils | 1 | 2013 | 307 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2601 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 736 | 0.020 |
Why?
|
| Chromatin | 1 | 2012 | 380 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2012 | 403 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 937 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1456 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 1135 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 1208 | 0.020 |
Why?
|